Education
About Us
Working with TipRanks
Follow Us
Daily Stock Ratings & Price Targets
Analyst Performance
Any
Analyst Rating
Any
Upside / Downside
Any
Action
Any
Market Cap
Any
Analyst & Firm | Company | Price | Rating & Price Target | Upside / Downside | Success Rate | Average Return | Action | Date | Article |
|---|---|---|---|---|---|---|---|---|---|
 | Linde | BUY $576 | ― | -4.60% | Initiated | RBC Capital Sticks to Their Buy Rating for Linde (LIN) | |||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $1,220 | ― | 21.80% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $349→$360 | ― | 9.90% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $140 | ― | 3.90% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $321→$332 | ― | 4.60% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $579 | ― | 7.90% | Downgraded | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD | ― | 6.10% | Upgraded | ||||
| Air Products and Chemicals | BUY $355 | ― | -4.60% | Initiated | Air Products initiated with an Outperform at RBC Capital | |||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $760 | ― | 11.60% | Downgraded | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $165→$210 | ― | 9.90% | Upgraded | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $6→$7 | ― | 1.20% | Upgraded | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $69 | ― | 14.40% | Initiated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $240 | ― | 12.80% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $213 | ― | 5.90% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $240 | ― | 12.80% | Reiterated | ||||
 | Kenvue, Inc. | HOLD $24.5 | ― | -1.70% | Reiterated | Kenvue, Inc.'s Strategic Moves and Market Position: Hold Rating Amid Limited Divestiture Plans | |||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $41 | ― | 25.50% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $260→$385 | ― | 16.50% | Upgraded | ||||
| Intellia Therapeutics | BUY $50 | ― | -5.30% | Reiterated | Intellia Therapeutics: Expert Confidence in Addressing Liver Enzyme Concerns Supports Buy Rating | |||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $35 | ― | 3.10% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $70 | ― | 4.80% | Reiterated | ||||
| Establishment Labs Holdings | BUY $62 | ― | -7.00% | Reiterated | Establishment Labs Holdings: Strong Growth Potential and Strategic Initiatives Drive Buy Rating | |||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $67→$80 | ― | 1.90% | Upgraded | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | SELL $60→$50 | ― | 1.90% | Downgraded | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $43 | ― | 2.20% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $32→$40 | ― | 1.90% | Upgraded | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | SELL $10→$9 | ― | 1.90% | Downgraded | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $17 | ― | 0.40% | Initiated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $77 | ― | 13.70% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $475 | ― | 3.70% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $80 | ― | 7.00% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $48→$47 | ― | 1.40% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | SELL $39→$42 | ― | 1.40% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $33→$35 | ― | 1.40% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $185 | ― | 48.90% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $50 | ― | 15.10% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $430→$470 | ― | 1.90% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $250→$275 | ― | 10.10% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $67→$70 | ― | 0.40% | Reiterated | ||||
| Fortrea Holdings Inc. | SELL $5 | ― | -8.90% | Reiterated | Barclays Sticks to Its Sell Rating for Fortrea Holdings Inc. (FTRE) | |||
 | Expand Energy | BUY $130→$135 | ― | -9.20% | Reiterated | Analysts Offer Insights on Energy Companies: Kinder Morgan (NYSE: KMI) and Expand Energy (NASDAQ: EXE) | |||
 | RH | BUY $436 | ― | -7.20% | Reiterated | RH (RH) Receives a Buy from Barclays | |||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $31 | ― | 16.50% | Reiterated | ||||
 | Nurix Therapeutics | BUY $31 | ― | -7.30% | Reiterated | Barclays Remains a Buy on Nurix Therapeutics (NRIX) | |||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $91 | ― | 16.50% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $990 | ― | 17.10% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $72 | ― | 7.80% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $50 | ― | 11.20% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $84 | ― | 17.10% | Reiterated | ||||
| Blueprint Medicines | HOLD $105→$129 | ― | -7.30% | Reiterated | Barclays Sticks to Their Hold Rating for Blueprint Medicines (BPMC) |
Rows:
